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Abstract 
Background: Amyloid-beta (Aβ) accumulation is a hallmark of Alzheimer’s disease (AD) that can lead to neuronal 
dysfunction and apoptosis. Tumor necrosis factor, alpha-induced protein 1 (TNFAIP1) is an apoptotic protein that 
was robustly induced in the transgenic C. elegans AD brains. However, the roles of TNFAIP1 in AD have not been 
investigated.
Results: We found TNFAIP1 protein and mRNA levels were dramatically elevated in primary mouse cortical neurons 
and Neuro2a (N2a) cells exposed to Aβ25–35. Knockdown and overexpression of TNFAIP1 significantly attenuated and 
exacerbated Aβ25–35-induced neurotoxicity in N2a cells, respectively. Further studies showed that TNFAIP1 knockdown 
significantly blocked Aβ25–35-induced cleaved caspase 3, whereas TNFAIP1 overexpression enhanced Aβ25–35-induced 
cleaved caspase 3, suggesting that TNFAIP1 plays an important role in Aβ25–35-induced neuronal apoptosis. Moreover, 
we observed that TNFAIP1 was capable of inhibiting the levels of phosphorylated Akt and CREB, and also anti-apop-
totic protein Bcl-2. TNFAIP1 overexpression enhanced the inhibitory effect of Aβ25–35 on the levels of p-CREB and Bcl-2, 
while TNFAIP1 knockdown reversed Aβ25–35-induced attenuation in the levels of p-CREB and Bcl-2.
Conclusion: These results suggested that TNFAIP1 contributes to Aβ25–35-induced neurotoxicity by attenuating Akt/
CREB signaling pathway, and Bcl-2 expression.
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Background
Alzheimer’s disease (AD) is a chronic neurodegenera-
tive disease that is characterized by the accumulation of 
amyloid-beta (Aβ) plaques, neurofibrillary tangles, and 
neuronal loss in various brain regions [1–3]. The 37–43 
amino acid Aβ fragments in the brain are originally 
derived from the β-amyloid precursor protein (APP) via 
proteolytic processing by β- and γ-secretase [4]. Aβ1–40 
and Aβ1–42 are two major neurotoxic Aβ fragments, 
which were mainly generated in the amyloidogenic pro-
cessing pathway by the actin of β- and γ-secretase [4]. 
Aβ25–35 is not naturally generated in the brain, instead it 
represents the neurotoxic fragment of Aβ1–40 or Aβ1–42, 
and therefore is often used to mimic the neurotoxic role 
of Aβ1–40 or Aβ1–42 in experimental studies [5]. Despite 
increasing evidence showing that Aβ could cause mor-
phological and biochemical characteristics of apoptosis 
such as chromatin condensation, DNA fragmentation, 
caspase activation and subsequent activation of apoptotic 
signaling pathways [6–8], the molecular mechanisms 
underlying the neurotoxic effect of Aβ have not been 
fully elucidated. Therefore, identification of key play-
ers and mechanisms of Aβ-induced neurotoxicity would 
benefit the development of novel therapeutic strategies 
for preventing and treating AD.
Tumor necrosis factor, alpha-induced protein 1 
(TNFAIP1) was originally identified as a gene whose 
expression can be induced by the tumor necrosis fac-
tor alpha (TNFα) in umbilical vein endothelial cells [9]. 
TNFAIP1 gene is found to be an evolutionarily extremely 
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conserved single-copy gene [9], implying that TNFAIP1 
has an important physiological role, which is yet to be 
explored. TNFAIP1 has been demonstrated to interact 
directly with proliferating cell nuclear antigen (PCNA) 
and the small subunit (p50) of DNA polymerase δ, imply-
ing that it may be involved in DNA synthesis or DNA 
repair [10, 11]. Kim et al. [12] found that RhoB induces 
apoptosis by interacting with TNFAIP1 via a JNK-medi-
ated signaling mechanism, suggesting that TNFAIP1 is an 
apoptosis-related protein. In addition, the transcription 
levels of TNFAIP1 had been found to be robustly induced 
in the transgenic C. elegans AD brains and post-mortem 
AD brain [13, 14], suggesting TNFAIP1 may also involve 
in the process of AD development. Moreover, a recent 
study implied that estrogen may affect hippocampal-
related diseases by regulating TNFAIP1 [15]. However, 
the role of TNFAIP1 in AD has not been demonstrated.
In the present study, we examined the roles of 
TNFAIP1 in Aβ25–35-induced apoptosis in neuronal cell 
line by testing whether the neuronal apoptosis induced 
by Aβ25–35 is associated with the expression of TNFAIP1 
protein, and if so, whether apoptosis can be blocked 
by inhibition of TNFAIP1 expression using TNFAIP1 
siRNA. In addition, to further clarify the signal transduc-
tion pathways involved in the neurotoxicity induced by 
Aβ, we also examined the potential signal transduction 
pathways involved in the apoptosis induced by TNFAIP1.
Our findings demonstrated that TNFAIP1 can be 
induced by Aβ25–35. Overexpression of TNFAIP1 pro-
motes Aβ25–35-induced neurotoxicity, whereas knock-
down of TNFAIP1 blocks Aβ25–35-induced neurotoxicity. 
In addition, our results suggested that TNFAIP1 induced 
by Aβ25–35 can further inactivate the Akt/CREB signaling 
pathway, which in turn downregulates Bcl-2 expression.
Methods
Cell culture and transfection
Animal experiments were following protocols approved 
by the Ethic Committee of Hunan Normal University, 
and the Institutional Animal Care and Use Commit-
tee of Massachusetts General Hospital in compliance 
with the NIH Guide for the Care and Use of Laboratory 
Animals. Primary mouse cortical neurons were isolated 
form 15  day embryonic cortex obtained from pregnant 
C57BL/6 female mouse as described before [16]. The cell 
pellets were resuspended in neuron basal medium, sup-
plemented with 2 % B27 supplement. Cells were seeded 
at a density of 3 × 105 cells/mL into 6 cm wells plate pre-
coated with poly-d-lysine. Medium was half changed 
every 4  days. All experiments were performed on cul-
tures at days 7–9 in vitro.
The mouse Neuro2A (N2a) neuroblastoma cell line 
was obtained from the American type culture collection 
(ATCC). The N2a cell line was cultured in a humidified 
(5  % CO2, 37  °C) incubator in DMEM supplemented 
with 10  % heat-inactivated FBS and 50  U/mL penicil-
lin/streptomycin (Invitrogen). The cells were seeded at 
1.5  ×  105  cells/mL in 24-wells plates or 6-wells plates. 
For transfection, N2a cells were grown on 24-wells plates 
to approximately 70  % confluence and then transiently 
transfected with Control siRNA and TNFAIP1 siRNA 
(Santa Cruz Biotechnology) or pCMV-myc and pCMV-
myc-TNFAIP1 (Myc-TNFAIP1, cloned previously [11]) 
using Lipotectamine™ 2000 (Invitrogen) following the 
manufacturer’s protocol.
Preparation of β‑amyloid fragment Aβ25–35
Aβ25–35 was purchased from Sigma-Aldrich, and dis-
solved in deionized distilled water at 1  mM and then 
aged for 5 days in a humid chamber at 37 °C before being 
added to the culture medium [17]. For treatment of cells, 
1 mM of Aβ25–35 was further added into the medium at 
a final concentration of 2, 5, 10 and 20 μM, respectively.
Cell viability assay
Cell viability was measured by MTT assay according 
to manufacturer’s protocol. N2a cells were grown on 
24-wells plates to approximately 70  % confluence and 
then transfected with TNFAIP1 siRNA or Myc-TNFAIP1 
for 24  h, followed by treatment of Aβ25–35 for another 
24  h. After treatments, cells were rinsed with PBS and 
replaced with fresh DMEM containing MTT. The cells 
were then incubated at 37 °C for 4 h under 5 % CO2/95 % 
air. After the medium was removed, DMSO was added 
into each well, the absorbance at 570 nm was measured 
on a microplate reader. Percentages of live cell counts 
were used for assay normalization.
Real‑time PCR
The RT-PCR primers for mouse TNFAIP1 and 18sRNA 
were purchased from SABiosciences. Total RNA from 
N2a cells was isolated with RNeasy Lipid Tissue Mini Kit 
(Qiagen) according to the manufacturer’s instructions. 
Then cDNA was synthesized with SuperScript system 
(Invitrogen). The mRNA levels of TNFAIP1 and 18sRNA 
were measured by quantitative RT-PCR using SYBR 
green kit (Applied Biosystems) in an ABI 7000 real-time 
PCR system (Applied Biosystems). The PCR conditions 
were as follows: Initial denaturation of DNA, 95  °C for 
5 min; denaturation, 32 cycles of 95 °C for 35 s; anneal-
ing, 60  °C for 35  s; extension, 72  °C for 35  s; and final 
extension, 72  °C for 5 min. Data were analyzed accord-
ing to the comparative threshold cycle method with 
expression for sample normalization. RT-PCR assay 
was performed in triplicate for each sample to ensure 
reproducibility.
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Western blot analysis
Mouse primary cortical neurons or N2a cells were rinsed 
with PBS, then lysed in cell lysis buffer containing pro-
tease inhibitors (Sigma). Equal amounts of total protein 
(20 μg) were separated using 4–12 % SDS-PAGE gel (Inv-
itrogen) and transferred onto nitrocellulose membrane 
(Invitrogen). The membrane was blocked with 5  % dry 
milk in 10 mM PBS buffer (pH 7.2) for 1 h at room tem-
perature. Immunoblots were then performed overnight at 
4 °C by incubation with the following primary antibodies: 
rabbit polyclonal antibodies against CREB (1:2000, Cell 
Signaling Technology), pCREB (1:1000, Cell Signaling 
Technology), AKT (1:1000, Cell Signaling Technology), 
pAKT (1:1000, Cell Signaling Technology), caspase-3 
(1:1000, Cell Signaling Technology), cleaved caspase-3 
(1:1000, Cell Signaling Technology), TNFAIP1 (1:500, 
Nanjing Chuanbo Biotech Co, Ltd, China), and mouse 
monoclonal β-actin antibody (1:5000, sigma), followed 
by incubation with horseradish peroxidase-conjugated 
secondary antibodies (1:5000, goat anti-mouse IgG-HRP 
or goat anti-rabbit IgG-HRP, Abmart) for 1  h at 37  °C. 
After washed by TTBS, immunolabeling was detected by 
enhanced chemiluminescence (ECL, Amersham Phar-
macia Biotech) according to the manufacturer’s protocol 
and then exposed to film (X-Omat; Eastman Kodak Co.).
Statistical analysis
Data were expressed as mean ± SD. Three to five sepa-
rate experiments were performed. Data were analyzed 
using ANOVA with Tukey post hoc tests (SPSS version 
18.0). Statistical significance was at p < 0.05.
Results
Aβ25–35 induces TNFAIP1 expression
To determine whether Aβ25–35 can increase the TNFAIP1 
protein expression, mouse primary cortical neurons were 
treated with Aβ25–35 at different doses for 24 h, and West-
ern blot was used to examine TNFIAP1 protein level. 
As shown in Fig. 1a, TNFAIP1 expression was increased 
by Aβ25–35 in a dose-dependent manner, and 5, 10 and 
20 μM of Aβ25–35 significantly upregulated TNFAIP1 pro-
tein levels (Fig. 1b). Similar results were obtained in N2a 
cells (Fig. 1c), as TNFAIP1 protein expression in N2a was 
also significantly increased by Aβ25–35 in a dose-depend-
ent manner (Fig.  1d). Furthermore, the endogenous 
TNFAIP1 mRNA levels in N2a cells were detected by 
Real-time PCR. As expected, Aβ25–35 treatment resulted 
in a significant increase in TNFAIP1 mRNA levels, and 
treatment with 20 μM of Aβ25–35 for 16 h led to the high-
est expression of TNFAIP1 mRNA, but prolonged 24  h 
treatment did not further increase the TNFAIP1 mRNA 
levels (Fig. 1e).
TNFAIP1 contributes to Aβ25–35‑induced cell toxicity in N2a 
cells
To further investigate whether TNFAIP1 is involved in 
Aβ25–35-induced cell death, N2a cells were transiently 
transfected with Control siRNA or TNFAIP1 siRNA for 
24 h, and then treated with indicated dose of Aβ25–35 for 
another 24 h. Western blot showed that the endogenous 
TNFAIP1 protein expression was significantly suppressed 
by specific TNFAIP1 siRNA but not Control siRNA 
(Fig.  2a). MTT assay indicated that the cell viability in 
Control siRNA transfected-N2a cells was significantly 
decreased when exposed to 10 or 20 μM of Aβ25–35. How-
ever, inhibition of TNFAIP1 by TNFAIP1 siRNA sig-
nificantly rescued the viability of N2a cells under 20 μM 
Aβ25–35 (Fig.  2b). Furthermore, to investigate whether 
TNFAIP1 is associated with increased susceptibil-
ity to Aβ25–35, the effect of TNFAIP1 overexpression on 
Aβ25–35-reduced the cell viability was also investigated. 
Transfection of Myc-TNFAIP1 into N2a cells led to sig-
nificant overexpression of TNFAIP1 protein (Fig.  2c), 
and Aβ25–35-induced cell death was further significantly 
exacerbated by TNFAIP1 overexpression (Fig. 2d). Taken 
together, these results indicate that TNFAIP1 contributes 
to Aβ25–35-induced cell toxicity of N2a cells.
TNFAIP1 contributes to Aβ25–35‑induced apoptosis
Previous study suggested that TNFAIP1 is an apoptosis-
related protein [12], implying that TNFAIP1 may also 
involve in Aβ25–35-induced apoptosis. Cleaved caspase-3 
is a pivotal executioner and hallmark of apoptosis that 
is usually activated in the apoptotic cell by both extrin-
sic and intrinsic pathways. To further determine whether 
involvement of TNFAIP1 in Aβ25–35-induced neuronal 
apoptosis is associated with changes in the activities 
of caspases, cleaved caspase-3 was detected by West-
ern blot. As shown in Fig.  3a, b, N2a cells treated with 
20 μM of Aβ25–35 led to a significant increase in the level 
of cleaved caspase-3, while Aβ25–35-induced caspase-3 
cleavage was significantly repressed by the knockdown 
of TNFAIP1. In contrast, 20 μM of Aβ25–35 treatment or 
Myc-TNFAIP1 transfection or Aβ25–35+Myc-TNFAIP1 
co-treatment exhibited a significant increase in the cleav-
age of caspase-3 (Fig.  3c, d). These results indicate that 
TNFAIP1 contributes to Aβ25–35-induced apoptosis.
TNFAIP1 inhibits Akt/CREB signaling pathway
It has been reported that Akt/CREB signaling plays 
neuroprotective roles [18] and Aβ could downregulate 
Akt survival pathway [19]. In agreement with previ-
ous studies, our results showed that Aβ25–35 causes a 
decrease in Akt phosphorylation (phosphor-Ser473), 
CREB phosphorylation (phosphor-Ser133-CREB) and 
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Bcl-2 expression in a dose-dependent manner (Fig.  4a). 
To further explore whether involvement of TNFAIP1 in 
neuronal apoptosis was associated with changes in Akt/
CREB signaling pathway, we overexpressed TNFAIP1 
in N2a cells in dose-dependent manner and then 
assessed Akt phosphorylation and CREB phosphoryla-
tion (Fig.  4a). As expected, overexpression of TNFAIP1 
in N2a cells led to significant attenuation of p-Akt and 
p-CREB in a dose-dependent manner (Fig. 4b–d). Impor-
tantly, we also observed that overexpression of TNFAIP1 
could significantly reduce the protein levels of Bcl-2 
(Fig.  4e), which is an important neuroprotectant and 
transactivated by CREB in response to Aβ stimulation 
[20]. Therefore, these results indicate that TNFAIP1 may 
mediate Aβ25–35-induced apoptotic signaling by attenuat-
ing p-Akt, p-CREB and Bcl-2 expression.
TNFAIP1 knockdown recovers Aβ25–35‑induced CREB 
dephosphrylation and Bcl‑2 downregulation
Aβ had been reported to dramatically decrease CREB 
phosphorylation and Bcl-2 expression [20, 21]. To inves-
tigate the roles of TNFAIP1 in Aβ25–35-reduced CREB 
phosphrylation and Bcl-2 expression, control siRNA or 
TNFAIP1 siRNA was transfected into N2a cells for 24 h, 
followed by treatment with 20 μM of Aβ25–35. Consistent 
with previous studies [20], Aβ25–35 treatment significantly 
reduced CREB phosphrylation and Bcl-2 expression. 
TNFAIP1 siRNA but not control siRNA significantly 
Fig. 1 Effect of Aβ25–35 on TNFAIP1 expression. a TNFAIP1 protein levels were measured by Western blot in mouse primary cortical neurons cultured 
in 6 wells plate and treated with dose-dependent Aβ25–35 (0–20 μM). b Quantitative analysis of TNFAIP1 protein levels (fold of control) in mouse pri-
mary cortical neurons. Data are expressed as mean ± SD, n = 4, *p < 0.05 compared with Aβ25–35 (0 μM) (PBS). c TNFAIP1 protein levels were meas-
ured by Western blot in N2a cells cultured in 6 wells plate and treated with dose-dependent Aβ25–35 (0–20 μM). d Quantitative analysis of TNFAIP1 
protein levels (fold of control) in N2a cells. Data are expressed as mean ± SD, n = 4, *p < 0.05 compared with Aβ25–35 (0 μM) (PBS). e TNFAIP1 mRNA 
levels were determined by RT-PCR in N2a cells cultured in 6 wells plate and treated with 20 μM of Aβ25–35. Data are expressed as mean ± SD, n = 3, 
*p < 0.05 compared with Aβ25–35 (0 h)
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upregulated CREB phosphorylation. However, TNFAIP1 
siRNA could partially attenuate the inhibitory effect 
of Aβ25–35 on p-CREB and Bcl-2 (Fig.  5). These results 
indicated that inhibition of TNFAIP1 could attenuate 
Aβ-induced neurotoxicity partially by recovering the 
inhibitory effect of Aβ on p-CREB and Bcl-2 expression.
TNFAIP1 contributes to Aβ25–35‑induced CREB 
dephosphrylation and Bcl‑2 downregulation
The effect of TNFAIP1 overexpression on CREB phos-
phrylation and Bcl-2 expression under resting and Aβ25–
35 treatment condition were also determined. Our results 
showed that 20 μM of Aβ25–35 or Aβ25–35+Myc-TNFAIP1 
had exhibited almost equivalent inhibitory effect on the 
p-CREB (Fig.  6a, b). Moreover, we also observed that 
20  μM of Aβ25–35 treatment, Myc-TNFAIP1 transfec-
tion, and Aβ25–35+Myc-TNFAIP1 co-treatment result in 
significant decrease in the expression of Bcl-2 (Fig.  6a, 
c). These results implied that TNFAIP1 maybe a key 
mediator involved in Aβ-induced neurotoxicity by inhibi-
tion of p-CREB and Bcl-2 expression.
Discussion
Deposition of Aβ in the brain is a pathological hallmark 
of AD as it is responsible for progressive neurodegen-
eration in AD [22]. Accumulating evidences indicated 
that Aβ could cause neurotoxicity by inducing neuronal 
apoptosis in  vitro and in  vivo [23, 24]. Elucidating the 
molecular mechanisms underlying Aβ-induced neuronal 
apoptosis will help us on developing treatment of AD. 
However, despite intense research, it remains unclear 
how Aβ triggers the signaling cascade that results in 
neuronal dysfunction and neurotoxicity. In the present 
study, our results demonstrated that TNFAIP1 protein 
is induced by Aβ25–35 and involved in Aβ25–35-induced 
neuronal apoptotic pathway because overexpression 
of TNFAIP1 can accelerate Aβ25–35-induced apoptosis 
while inhibition of TNFAIP1 can significantly reduce 
Fig. 2 Effect of TNFAIP1 on Aβ25–35-induced neuronal cell death. a TNFAIP1 protein levels were measured by Western blot in N2a cells cultured in 12 
wells plate and transfected with 20 pmol of Control siRNA or TNFAIP1 siRNA. b MTT reduction was measured by MTT assay in N2a cells cultured in 
12 wells plate and transfected with 20 pmol of Control siRNA or TNFAIP1 siRNA, followed by treated by dose-dependent Aβ25–35 (0–20 μM). Data are 
expressed as mean ± SD, n = 4, *p < 0.05 compared with Aβ25–35 (0 μM), #p < 0.05 compared with Control siRNA plus Aβ25–35 (20 μM).  
c Myc-TNFAIP1 protein levels were measured by Western blot in N2a cells cultured in 12 wells plate and transfected with 1.2 μg of pCMV-Myc or 
Myc-TNFAIP1. d MTT reduction was measured by MTT assay in N2a cells cultured in 12 wells plate and transfected with dose-dependent Myc-
TNFAIP1 (0–1.2 μg), followed by treated by PBS or Aβ25–35 (20 μM). Data are expressed as mean ± SD, n = 4, *p < 0.05 compared with Myc-TNFAIP1 
(0 μg) plus PBS. #p < 0.05 compared with Myc-TNFAIP1 plus PBS
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Aβ25–35-induced neuronal apoptosis. Moreover, we found 
that TNFAIP1 was involved in Aβ25–35-induced neuronal 
apoptosis by deactivating Akt signaling pathway and 
CREB transcriptional activity.
The transcript levels of TNFAIP1 was found to be 
robustly induced in the transgenic C. elegans AD brains 
and post-mortem AD brain in previous study [12, 13], 
which led us to examine the hypothesis that TNFAIP1 
was involved in the pathological development of AD 
using an in  vitro mouse AD model: mouse primary 
cortical neurons and N2a neuroblastoma cells treated 
by Aβ25–35. Our results suggested that Aβ25–35 could 
induce TNFAIP1 protein and mRNA levels in a dose-
dependent manner. Furthermore, overexpression or 
knockdown of TNFAIP1 exacerbated or alleviated Aβ25–
35-induced neurotoxicity. Together, these results indi-
cated that the TNFAIP1 gene expression may be critical 
for Aβ25–35-induced neuronal death and intervention of 
its expression could be a potential method for inhibit-
ing Aβ25–35-induced neurotoxicity. However, the regula-
tory mechanisms of TNFAIP1 remain largely unclear. 
Only a recent report described that transcription factor 
Sp1 could bind to human TNFAIP1  promoter region and 
transactivate  TNFAIP1 promoter [25]. As TNFAIP1 had 
been originally found to be induced by TNFα [9], which 
is a potent activator of NFκB, thus it is possible that 
TNFAIP1 was also regulated by NFκB when exposed to 
Aβ25–35. Further studies will be performed to elucidate 
whether inhibition of NFκB activation can reduce Aβ25–
35-induced TNFAIP1 gene expression.
Previous studies described that TNFAIP1 was a pro-
apoptotic protein [12], and apoptosis is a general neu-
ronal death pathway in neurodegenerative diseases which 
could be triggered by exposure to Aβ. In the present 
study, we extended our observations to in vitro AD mod-
els that TNFAIP1 was also involved in Aβ25–35-induced 
apoptosis. We found that inhibition of TNFAIP1 gene by 
specific siRNA significantly attenuated Aβ25–35 induced 
cleaved-caspase 3. As caspase-3 cleavage is a central 
event in executing Aβ25–35-induced neuronal apopto-
sis [26, 27], these results provide further evidence that 
TNFAIP1 was involved in Aβ25–35-induced apoptosis. 
However, it is worth noting that Aβ25–35+Myc-TNFAIP1 
co-treatment did not cause a much higher increase in 
the cleavage of caspase-3 than Aβ25–35 treatment or Myc-
TNFAIP1 transfection alone. It is possible that 20 μM of 
Fig. 3 Effect of TNFAIP1 on Aβ25–35-induced the cleavage of caspase-3. a Cleaved caspase-3 protein levels were measured by Western blot in N2a 
cells cultured in 6 wells plate and transfected with 50 pmol of Control siRNA or TNFAIP1 siRNA, followed by treated by Aβ25–35 (20 μM). b Quantita-
tive analysis of Cleaved caspase-3 protein levels (fold of control) in N2a cells. Data are expressed as mean ± SD, n = 3, *p < 0.05 compared with 
Control siRNA, #p < 0.05 compared with Control siRNA plus Aβ25–35 (20 μM). c Cleaved caspase-3 protein levels were measured by Western blot in 
N2a cells cultured in 6 wells plate and transfected with 4 μg of pCMV-Myc or Myc-TNFAIP1, followed by treated by Aβ25–35 (20 μM). d Quantitative 
analysis of Cleaved caspase-3 protein levels (fold of control) in N2a cells. Data are expressed as mean ± SD, n = 3, *p < 0.05, **p < 0.01 compared 
with pCMV-Myc
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Aβ25–35 treatment or Myc-TNFAIP1 transfection alone 
had already exerted a relatively strong apoptotic effect 
on N2a cells, which led to a insignificant effect on cas-
pase 3 cleavage by additional other stimuli. This issue will 
be further defined in future studies. Thus, these results 
are in support of the hypothesis that the induction of 
TNFAIP1 expression is part of the intrinsic program of 
apoptotic neuronal death induced by accumulation of Aβ 
in AD.
It had been demonstrated that CREB is directly phos-
phorylated and regulated by the protein kinase Akt [28], 
and Akt/CREB signal has been shown to play a pivotal 
role in neuroprotection by enhancing cell survival and 
inhibiting apoptosis [18]. Importantly, Akt and CREB 
could promote neuronal cell survival by upregulating 
Bcl-2 protein levels [29]. As expected, TNFAIP1 could 
reduce p-Akt, p-CREB and Bcl-2 protein levels in a dose-
dependent manner. Moreover, we observed overexpres-
sion of TNFAIP1 could further attenuate Aβ-inhibited 
p-CREB and Bcl-2 protein expression, whereas inhibi-
tion of TNFAIP1 could significantly reverse the effect 
of Aβ on p-CREB and Bcl-2. These results suggest that 
TNFAIP1 may mediate the deactivation of CREB induced 
by Aβ, and then trigger neuronal apoptosis. MAPKs had 
been reported to be involved in Aβ-induced apoptosis, 
and MAPKs signaling cascades were activated in brains 
from AD patients [30]. Moreover, Aβ-induced MAPKs 
include ERK1/2, JNK and p38 MAPK had been demon-
strated to be associated with neuronal cell death [31, 32]. 
Therefore, TNFAIP1 may also modulate MAPKs signal-
ing cascades involved in Aβ-induced neuronal apopto-
sis. Further study will be conducted to elucidate the role 
Fig. 4 Effect of Aβ25–35 and TNFAIP1 on p-Akt, p-CREB and Bcl-2 expression. a p-Akt, p-CREB and Bcl-2 protein levels were measured by Western 
blot in N2a cells cultured in 6 wells plate and treated with dose-dependent Aβ25–35 (0–20 μM). b p-Akt, p-CREB and Bcl-2 protein levels were 
measured by Western blot in N2a cells cultured in 6 wells plate and transfected with Myc-TNFAIP1 and pCMV-Myc (0–4 μg). c Quantitative analysis 
of p-CREB protein levels (fold of control). Data are expressed as mean ± SD, n = 3, *p < 0.05, **p < 0.01 compared with Myc-TNFAIP1 (0 μg). d 
Quantitative analysis of p-Akt protein levels (fold of control). Data are expressed as mean ± SD, n = 3, *p < 0.05 compared with Myc-TNFAIP1 (0 μg). 
e Quantitative analysis of Bcl-2 protein levels (fold of control). Data are expressed as mean ± SD, n = 3, *p < 0.05 compared with Myc-TNFAIP1 (0 μg)
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of TNFAIP1 in modulating MAPKs signaling pathway 
involved in the apoptotic effect of Aβ.
In summary, in this study we found that TNFAIP1 
expression was elevated in mouse primary cortical neu-
rons and N2a cells exposed to Aβ25–35. TNFAIP1 over-
expression was correlated with neuronal apoptosis 
initiated by Aβ25–35 and inhibition of TNFAIP1 was 
able to reduce the neuronal damage induced by Aβ25–35 
in vitro AD models. Moreover, our results suggested that 
TNFAIP1 may mediate Aβ25–35-induced neuronal dam-
age by inhibiting p-CREB and Bcl-2 protein levels. Our 
results implied that inhibition of TNFAIP1 gene during 
Fig. 5 Effect of TNFAIP1 knockdown on Aβ25–35-decreased Bcl-2 
and p-CREB. a Bcl-2 and p-CREB protein levels were measured by 
Western blot in N2a cells cultured in 6 wells plate and transfected 
with 50 pmol of Control siRNA or TNFAIP1 siRNA, followed by treated 
by Aβ25–35 (20 μM). b Quantitative analysis of p-CREB protein levels 
(fold of control). Data are expressed as mean ± SD, n = 3, *p < 0.05, 
**p < 0.01 compared with Control siRNA, #p < 0.05 compared with 
Control siRNA plus Aβ25-35 (20 μM). (C). Quantitative analysis of Bcl-2 
protein levels (fold of control). Data are expressed as mean ± SD, 
n = 3, *p < 0.05 compared with Control siRNA
Fig. 6 Effect of TNFAIP1 overexpression on Aβ25–35-decreased Bcl-2 
and p-CREB. a Bcl-2 and p-CREB protein levels were measured by 
Western blot in N2a cells cultured in 6 wells plate and transfected 
with 4 μg of pCMV-Myc or Myc-TNFAIP1, followed by treated by 
Aβ25–35 (20 μM). b Quantitative analysis of p-CREB protein levels 
(fold of control). Data are expressed as mean ± SD, n = 3, *p < 0.05, 
**p < 0.01 compared with pCMV-Myc. c Quantitative analysis of Bcl-2 
protein levels (fold of control). Data are expressed as mean ± SD, 
n = 3, *p < 0.05, **p < 0.01 compared with pCMV-Myc
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AD process could be a potential therapeutic strategy for 
treatment of AD. Further studies will be performed to 
determine the roles of TNFAIP1 in in vivo AD models.
Conclusions
In summary, this study clearly demonstrated that 
TNFAIP1 was significantly upregulated by Aβ25–35 in 
mouse primary cortical neurons and N2a cells, and 
TNFAIP1 may be a key player that mediated Aβ25–35-
induced neurotoxicity by inactivating the Akt/CREB 
signaling pathway, and in turn downregulating anti-apop-
totic protein Bcl-2. Our findings implied that TNFAIP1 
may be a potential therapeutic target for treatment of 
AD, but the roles and mechanism of TNFAIP1 in in vivo 
AD models need to be further elucidated in our future 
study.
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